Citation index

Michael A. Nauck, MD

Ruhr University Bochum, Diabetes Division, Bad Lauterberg im Harz

Diabetologist and endocrinologist whose research defined the incretin effect and its impairment in type 2 diabetes, and who contributed clinical trial leadership across the GLP-1 receptor agonist and oral semaglutide programs.